A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
Status:
ENROLLING_BY_INVITATION
Trial end date:
2031-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 multicenter trial in 2 parts to evaluate the long-term safety and efficacy of navenibart in adult and adolescent participants with hereditary angioedema (HAE) who participated in STAR-0215-301 (NCT06842823; ALPHA-ORBIT). Part 1 provides all participants with navenibart in a dose-controlled fashion; Part 2 introduces a personalized dosing option (PDO) for participants based on individual needs.